

## NuProbe, Qiagen to explore NGS based cancer tests

19 March 2020 | News

NuProbe and QIAGEN will explore integrating their two amplicon based enrichment and sequencing technologies



NuProbe Global, a global molecular diagnostics company based in Shanghai and Suzhou, China and Houston, TX, have announced it has entered into a collaboration agreement with QIAGEN to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy.

Under terms of the collaboration agreement, NuProbe and QIAGEN will explore integrating their two amplicon-based enrichment and sequencing technologies: NuProbe's proprietary Blocker Displacement Amplification (BDA) technology and QIAGEN's Single Primer Extension (SPE) technology, for accurate and affordable analysis of DNA mutations with very low variant allele fractions and to advance non-invasive cancer genomic profiling.

The QIAGEN and NuProbe teams will initially work on developing research use only products, for clinical researchers in oncology. The two companies may explore further strategic collaboration and develop other commercial products in the future.